TRIDENT LIFELINE LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 155 INR | +0.65% |
|
-1.90% | -17.55% |
| Apr. 27 | Trident Lifeline Limited Announces Board and Committee Changes | CI |
| Apr. 27 | Trident Lifeline Limited Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2022 | 218M 2.61M | Sales 2023 | 317M 3.8M | Capitalization | 1.83B 21.91M |
|---|---|---|---|---|---|
| Net income 2022 | 22M 263K | Net income 2023 | 60M 719K | EV / Sales 2022 * | - |
| Net Debt 2022 | 23.24M 278K | Net cash position 2023 | 81.46M 976K | EV / Sales 2023 | 5.52 x |
| P/E ratio 2022 * |
-
| P/E ratio 2023 |
25.5
x | Employees | 36 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 19.06% |
More Fundamentals
* Assessed data
More news
| 1 day | +0.65% | ||
| 1 week | -1.90% | ||
| Current month | -3.12% | ||
| 1 month | -6.06% | ||
| 3 months | -18.42% | ||
| 6 months | -17.77% | ||
| Current year | -17.55% |
1 week
151.00
171.00
1 month
140.05180.00
Current year
136.00212.80
1 year
128.25239.70
3 years
102.75239.70
5 years
102.75239.70
10 years
102.75239.70
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 30 | 22-06-26 | |
| Director of Finance/CFO | 39 | 20-09-30 | |
| Compliance Officer | - | Dec. 10 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 46 | 15-02-25 | |
Maniya Desai
BRD | Director/Board Member | 39 | 22-06-26 |
| Director of Finance/CFO | 39 | 20-09-30 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 155 | +0.65% | 4,800 |
| 24-05-09 | 154 | -3.51% | 6,000 |
| 24-05-08 | 159.6 | -5.00% | 3,600 |
| 24-05-07 | 168 | +5.40% | 7,800 |
| 24-05-06 | 159.4 | +0.89% | 47,400 |
Delayed Quote Bombay S.E., May 10, 2024 at 06:00 am EDT
More quotes
Trident Lifeline Limited is an India-based pharmaceutical company, which is engaged in providing of capsules, tablets, liquid ointment, gel, ice gel, mouthwash, paste, solution, suspension, dry powders, and toothpaste. The Company operates through seven geographical segments: India, Ghana, Kenya, Nigeria, Cameroon, Venezuela, Rest of World. The Company offers a range of pharmaceutical formulations and products manufactured on contract manufacturing under loan license. It deals in capsules, tablets, liquid ointment, gel, ice gel, mouthwash, paste, solution, suspension, dry powders, and toothpaste. Its product portfolio includes a range of drugs like Anti-Bacterial, Anti Diarrheal, Anti-Fungal, Anti-Malarial, Anti Diabetic, Dental Cure, Proton Pump Inhibitor, Anti Protozoal, Anti Histamine, Anti-Hypertensive drugs, Anti Lipidemic Drug, Anti Parasitic, Multivitamin, Multimineral, Nutraceutical, Non-Steroidal Anti-Inflammatory Drug (NSAIDS).
Sector
Pharmaceuticals
Calendar
2024-07-14
- Q1 2025 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -17.55% | 21.34M | |
| +30.38% | 684B | |
| +26.51% | 568B | |
| -4.36% | 361B | |
| +19.30% | 329B | |
| +3.73% | 284B | |
| +16.70% | 240B | |
| +8.78% | 208B | |
| -7.93% | 200B | |
| +7.68% | 166B |
- Stock Market
- Equities
- 543616 Stock
